RxDoctor Payments Data

Ana Otero, MD

General Practice · Barceloneta, PRNPI 1740278449

Payments from drug & device makers

$710in general payments, 2019–2025

Across 33 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$525
  • Boehringer Ingelheim$53
  • Eli Lilly Export S.A. Puerto Rico Branch$47
  • E.r. Squibb & Sons, L.L.C.$40
  • Merck$24
  • PBG Puerto Rico LLC$11
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$710100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca23$525
Boehringer Ingelheim3$53
Eli Lilly Export S.A. Puerto Rico Branch2$47
E.r. Squibb & Sons, L.L.C.2$40
Merck1$24
PBG Puerto Rico LLC1$11
Pfizer Pharmaceuticals LLC1$11

How this compares

$710 in reported general payments places this provider in the 80th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,871
Medicare patients
16
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate150$95,817
JanumetSitagliptin Phos/Metformin Hcl179$94,414
FarxigaDapagliflozin Propanediol106$64,701
EliquisApixaban54$32,596
Trijardy XrEmpaglifloz/Linaglip/Metformin63$30,301
SynthroidLevothyroxine Sodium360$29,821
TradjentaLinagliptin45$28,379
XareltoRivaroxaban35$25,126
TrulicityDulaglutide25$24,650
SynjardyEmpagliflozin/Metformin Hcl40$23,507
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate81$22,339
OzempicSemaglutide20$19,492
JentaduetoLinagliptin/Metformin Hcl38$17,737
LantusInsulin Glargine,hum.Rec.Anlog202$17,306
CreonLipase/Protease/Amylase17$13,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$24$190,231329 claims
Boehringer IngelheimTrijardy Xr, Tradjenta, Synjardy, Jentadueto, Jardiance$53$113,314202 claims
AstraZenecaFarxiga, Brilinta$525$70,592119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Barceloneta

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →